All In Biotech

NDA 021670 · Dorc

Visionblue

Trypan Blue · Ophthalmic

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Dec 16, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 1 recruiting

FAERS reports

44

43 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 17, 2026.

Indications & Usage VisionBlue® 0.06% is indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens. VisionBlue® 0.06% is a diagnostic dye indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens.

Mechanism: Mechanism of action VisionBlue® 0.06% selectively stains connective tissue structures in the human eye such as the anterior lens capsule of the human crystalline lens. VisionBlue® 0.06% is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. Excess dye is washed out of the anterior chamber. The dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non-stained lens cortex and inner lens material.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 16, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewLetter
1 products under this application
  • VISIONBLUE · TRYPAN BLUE 0.06% · SOLUTION, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trypan Blue" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxic anterior segment syndrome24
  • blindness21
  • corneal oedema10
  • product quality issue6
  • cerebral infarction3
  • endophthalmitis3
  • off label use3
  • pigmentation disorder3
  • thyroid disorder3
  • condition aggravated2
  • vision blurred2
  • corneal decompensation1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
201421
20166
20176
20184
20191
20213
20221
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 87 on PubMed

Sponsor: Dorc

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.